Dr Malik is a world renowed scientist in the area of vascular biology and mechanisms underlying acute lung injury and its more sever form acute respiratory distress syndrome. The original discovery that albumin nanoparticles carrying piceatannol can preferentially target actived neutrophils and supress inflammation was made by his group (Nature Nanotech 2014).
Dr Kanteti is a pharmacologist with extensive background in drug development, immunology, and cancer biology. He has signficant experience in launching start-ups and oversees drug development and bringing them to fruition.
Dr Stuart is an engineer with a strong chemistry and biology background. He is also an expert in the preparation and formulation of albumin nanoparticles and his current efforts are directed at scaling up production yield. In addition, he also has experience in startup environments.
Follow for Updates
Whether you are a scientist, investor or just curious, subscribe to stay informed on the latest news.
